This company has been acquired
Covetrus Valuation
Is CVET undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Por debajo del valor justo
Muy por debajo del valor justo
Price-To-Sales vs. similares
Price-To-Sales vs. Industria
PM vs. Ratio Justo
Pronóstico de los analistas
Share Price vs Fair Value
What is the Fair Price of CVET when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Por debajo del valor justo: CVET ($20.99) is trading below our estimate of fair value ($30.36)
Muy por debajo del valor justo: CVET is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CVET?
Other financial metrics that can be useful for relative valuation.
What is CVET's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$2.94b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 0.9x |
Enterprise Value/EBITDA | 23.4x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does CVET's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 0.4x | ||
PDCO Patterson Companies | 0.4x | 3.1% | US$2.4b |
OMI Owens & Minor | 0.2x | 3.0% | US$2.1b |
AHCO AdaptHealth | 0.4x | 5.6% | US$1.4b |
HSIC Henry Schein | 0.8x | 5.9% | US$9.3b |
CVET Covetrus | 0.6x | 5.6% | US$2.9b |
Price-To-Sales vs. similares: CVET is expensive based on its Price-To-Sales Ratio (0.6x) compared to the peer average (0.6x).
Price to Earnings Ratio vs Industry
How does CVET's PE Ratio compare vs other companies in the US Healthcare Industry?
Price-To-Sales vs. Industria: CVET is good value based on its Price-To-Sales Ratio (0.6x) compared to the US Healthcare industry average (1.2x)
Price to Sales Ratio vs Fair Ratio
What is CVET's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 0.6x |
Fair PS Ratio | 0.9x |
PM vs. Ratio Justo: CVET is good value based on its Price-To-Sales Ratio (0.6x) compared to the estimated Fair Price-To-Sales Ratio (0.9x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | n/a | US$21.50 0% | 2.3% | US$22.00 | US$21.00 | n/a | 2 |
Mar ’25 | n/a | US$21.50 0% | 2.3% | US$22.00 | US$21.00 | n/a | 2 |
Feb ’25 | n/a | US$21.50 0% | 2.3% | US$22.00 | US$21.00 | n/a | 2 |
Jan ’25 | n/a | US$21.50 0% | 2.3% | US$22.00 | US$21.00 | n/a | 2 |
Dec ’24 | n/a | US$21.50 0% | 2.3% | US$22.00 | US$21.00 | n/a | 2 |
Nov ’24 | n/a | US$21.50 0% | 2.3% | US$22.00 | US$21.00 | n/a | 2 |
Oct ’24 | n/a | US$21.50 0% | 2.3% | US$22.00 | US$21.00 | n/a | 2 |
Sep ’24 | n/a | US$21.50 0% | 2.3% | US$22.00 | US$21.00 | n/a | 2 |
Aug ’24 | n/a | US$21.50 0% | 2.3% | US$22.00 | US$21.00 | n/a | 2 |
Jul ’24 | n/a | US$21.50 0% | 2.3% | US$22.00 | US$21.00 | n/a | 2 |
Jun ’24 | n/a | US$21.50 0% | 2.3% | US$22.00 | US$21.00 | n/a | 2 |
May ’24 | n/a | US$21.50 0% | 2.3% | US$22.00 | US$21.00 | n/a | 2 |
Apr ’24 | n/a | US$21.50 0% | 2.3% | US$22.00 | US$21.00 | n/a | 2 |
Mar ’24 | n/a | US$21.50 0% | 2.3% | US$22.00 | US$21.00 | n/a | 2 |
Feb ’24 | n/a | US$21.50 0% | 2.3% | US$22.00 | US$21.00 | n/a | 2 |
Jan ’24 | n/a | US$21.50 0% | 2.3% | US$22.00 | US$21.00 | n/a | 2 |
Dec ’23 | n/a | US$21.50 0% | 2.3% | US$22.00 | US$21.00 | n/a | 2 |
Nov ’23 | n/a | US$21.50 0% | 2.3% | US$22.00 | US$21.00 | n/a | 2 |
Oct ’23 | US$20.88 | US$21.33 +2.2% | 2.2% | US$22.00 | US$21.00 | n/a | 3 |
Sep ’23 | US$20.82 | US$21.33 +2.5% | 2.2% | US$22.00 | US$21.00 | n/a | 3 |
Aug ’23 | US$20.81 | US$21.33 +2.5% | 2.2% | US$22.00 | US$21.00 | n/a | 3 |
Jul ’23 | US$20.85 | US$21.33 +2.3% | 2.2% | US$22.00 | US$21.00 | n/a | 3 |
Jun ’23 | US$20.68 | US$21.33 +3.2% | 2.2% | US$22.00 | US$21.00 | n/a | 3 |
May ’23 | US$13.80 | US$25.80 +87.0% | 27.9% | US$38.00 | US$18.00 | n/a | 5 |
Apr ’23 | US$17.01 | US$25.80 +51.7% | 27.9% | US$38.00 | US$18.00 | n/a | 5 |
Pronóstico de los analistas: Target price is less than 20% higher than the current share price.